Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases

Respiratory Medicine

Volumn 134, Issue , 2018, Pages 16-23

  Ferguson, Gary T ^a   Hickey, Anthony J ^b   Dwivedi, Sarvajna ^c  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

^b RTI INTERNATIONAL   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Drug delivery; Drug formulation; Inhaled drugs; Pressurized metered dose inhalers

Indexed keywords

PHOSPHOLIPID; RESPIRATORY TRACT AGENT;

AEROSOL; COMBINATION DRUG THERAPY; CRYSTAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SUSPENSION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; METERED DOSE INHALER;

ADMINISTRATION, INHALATION; ASTHMA; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; EQUIPMENT DESIGN; HUMANS; LUNG; METERED DOSE INHALERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS;

EID: 85034966981     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.09.012     Document Type: Review

References (64)

1. Nakawah, M.O., Hawkins, C., Barbandi, F., Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J. Am. Board Fam. Med. 26:4 (2013), 470–477.
2. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report Department of Health and Human Services (Ed.), 2007 Bethesda, MD.
3. Laube, B.L., Janssens, H.M., de Jongh, F.H.C., Devadason, S.G., Dhand, R., Diot, P., Everard, M.L., Horvath, I., Navalesi, P., Voshaar, T., Chrystyn, H., What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 37:6 (2011), 1308–1417.
4. Anderson, P.J., History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care 50:9 (2005), 1139–1150.
5. Rubin, B.K., Fink, J.B., Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care 50:9 (2005), 1191–1200.
6. Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention. 2016 www.ginasthma.org (Last Accessed 7 April 2017).
7. Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management, and Preventions of Chronic Obstructive Pulmonary Disease. 2017 www.goldcopd.org (Last Accessed 7 April 2017).
8. Vincken, W., Dekhuijzen, R., Barnes, P.J., ADMIT Group, The ADMIT series - issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim. Care Respir. J. 19:1 (2009), 10–20.
9. Fletcher, C., Peto, R., The natural history of chronic airflow obstruction. Br. Med. J. 1:6077 (1977), 1645–1648.
10. Lange, P., Parner, J., Vestbo, J., Schnohr, P., Jensen, G., A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 339:17 (1998), 1194–1200.
11. Labiris, N.R., Dolovich, M.B., Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56:6 (2003), 600–612.
12. Lavorini, F., The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy, 2013, 2013, 102418.
13. Chrystyn, H., The Diskus™: a review of its position among dry powder inhaler devices. Int. J. Clin. Pract. 61:6 (2007), 1022–1036.
14. Crowder, T.M., Donovan, M.J., Chapter 9: Science and Technology of Dry Powder Inhalers. Smyth, H.D.C., Hickey, A.J., (eds.) Controlled Pulmonary Drug Delivery, 2011, Springer, New York, NY, USA, 203–222.
15. Geller, D.E., New liquid aerosol generation devices: systems that force pressurized liquids through nozzles. Respir. Care 47:12 (2002), 1392–1404.
16. Ganguly, A., Das, A.K., Roy, A., Adhikari, A., Banerjee, J., Sen, S., Study of proper use of inhalational devices by bronchial asthma or COPD patients attending a tertiary care hospital. J. Clin. Diag. Res. 8:10 (2014), HC04–HC07.
17. Virchow, J.C., Crompton, G.K., Dal Negro, R., Pedersen, S., Magnan, A., Seidenberg, J., Barnes, P.J., Importance of inhaler devices in the management of airway disease. Respir. Med. 102:1 (2008), 10–19.
18. Dekhuijzen, P.N.R., Vincken, W., Virchow, J.C., Roche, N., Agusti, A., Lavorini, F., van Aalderen, W.M., Price, D., Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir. Med. 107:12 (2013), 1817–1821.
19. Georgopoulos, D., Mouloudi, E., Kondili, E., Klimathianaki, M., Bronchodilator delivery with metered-dose inhaler during mechanical ventilation. Crit. Care 4:4 (2000), 227–234.
20. Janssens, W., VandenBrande, P., Hardeman, E., De Langhe, E., Philps, T., Troosters, T., Decramer, M., Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur. Respir. J. 31:1 (2008), 78–83.
21. Newman, S.P., Principles of metered-dose inhaler design. Respir. Care 50:9 (2005), 1177–1190.
22. Dolovich, M.B., Dhand, R., Aerosol drug delivery: developments in device design and clinical use. Lancet 377:9770 (2011), 1032–1045.
23. Hochrainer, D., Hölz, H., Kreher, C., Scaffidi, L., Spallek, M., Wachtel, H., Comparison of the aerosol velocity and spray duration of Respimat Soft Mist™ inhaler and pressurized metered dose inhalers. J. Aerosol Med. 18:3 (2005), 273–282.
24. Rogueda, P., Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin. Drug Deliv. 2:4 (2005), 625–638.
25. Vehring, R., Lechuga-Ballesteros, D., Joshi, V., Noga, B., Dwivedi, S.K., Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 28:42 (2012), 15015–15023.
26. Cummings, R.H., Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition—valve performance. J. Allergy Clin. Immunol. 104:6 (1999), s230–s235.
27. Selvam, P., Peguin, R.P.S., Chokshi, U., da Rocha, S.R.P., Surfactant design for the 1,1,1,2-tetrafluoroethane−water interface: ab initio calculations and in situ high-pressure tensiometry. Langmuir 22:21 (2006), 8675–8683.
28. Conti, D.S., Grashik, J., Yang, L., Wu, L., da Rocha, S.R., Solvation in hydrofluoroalkanes: how can ethanol help?. J. Pharm. Pharmacol. 64:9 (2012), 1236–1244.
29. Usmani, O.S., Biddiscombe, M.F., Barnes, P.J., Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am. J. Respir. Crit. Care Med. 172:12 (2005), 1497–1504.
30. Patton, J.S., Byron, P.R., Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6:1 (2007), 67–74.
31. Fernández Tena, A., Casan Clarà, P., Deposition of inhaled particles in the lungs. Arch. Bronconeumol 48:7 (2012), 240–246.
32. Bennett, W.D., Smaldone, G.C., Human variation in the peripheral air-space deposition of inhaled particles. J. Appl. Physiol. 62:4 (1987), 1603–1610.
33. Weers, J.G., Bell, J., Chan, H.-K., Cipolla, D., Dunbar, C., Hickey, A.J., Smith, I.J., Pulmonary formulations: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv., 23(S2), 2010 S-5–S-23.
34. Shi, L., Plumley, C.J., Berkland, C., Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir 23:22 (2007), 10897–10901.
35. Restrepo, R.D., Alvarez, M.T., Wittnebel, L.D., Sorenson, H., Wettstein, R., Vines, D.L., Sikkema-Ortiz, J., Gardner, D.D., Wilkins, R.L., Medication adherence issues in patients treated for COPD. Int. J. Chron. Obstruct. Pulmon Dis. 3:3 (2008), 371–384.
36. Lechuga-Ballesteros, D., Noga, B., Vehring, R., Cummings, R.H., Dwivedi, S.K., Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med. Chem. 3:13 (2011), 1703–1718.
37. Lechuga-Ballesteros, D., Joshi, V., Sommerville, M., Golden, M., Vehring, R., Noga, B., Cummings, H., Schultz, R., Orevillo, C., Reisner, C., Dwivedi, S.K., Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD. Eur. Respir. J., 40(Suppl 56), 2012 Abstract P2152.
38. D. Lechuga-Ballesteros, R. Vehring, V. Joshi, B. Noga, R. Schultz, H. Cummings, M. Golden, C. Orevillo, C. Reisner, S. Dwivedi, Triple drug fixed dose combination metered dose inhaler with stable and equivalent drug delivery performance relative to individual and dual subcomponents, presented at: American Thoracic Society (ATS) 2012 International Conference; May 18–23, 2012; San Francisco, California.
39. V. Joshi, D. Lechuga-Ballesteros, B. Flynn, R. Vehring, R.D. Schultz, B. Noga, H. Cummings, J.H. Speck, S.K. Dwivedi, Development of mono, dual and triple combination pMDIs without co-formulation effect, presented at: Respiratory Drug Delivery Europe (RDD Europe 2011) Meeting; May 3–6, 2011; Berlin, Germany.
40. Dellamary, L.A., Tarara, T.E., Smith, D.J., Woelk, C.H., Adractas, A., Costello, M.L., Gill, H., Weers, J.G., Hollow porous particles in metered dose inhalers. Pharmacol. Res. 17:2 (2000), 168–174.
41. Leach, C., Davidson, P., Boudreau, R., Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 12:6 (1998), 1346–1353.
42. Hirst, P.H., Pitcairn, G.R., Weers, J.G., Tarara, T.E., Clark, A.R., Dellamary, L.A., Hall, G., Shorr, J., Newman, S.P., In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm. Res. 19:3 (2002), 258–264.
43. Duddu, P., Sisk, S.A., Walter, Y.H., Tarara, T.E., Trimble, K.R., Clark, A.R., Eldon, M.A., Elton, R.C., Pickford, M., Hirst, P.H., Newman, S.P., Weers, J.G., Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. 19:5 (2002), 689–695.
44. Joshi, V., Noga, B., Lechuga-Ballesteros, D., Schultz, R., Cummings, H., Golden, M., Orevillo, C.J., Reisner, C., Dwivedi, S.K., Nanogram level in vitro dose proportionality and stability of glycopyrrolate and formoterol fumarate in a novel cosuspension metered dose inhaler format. Am. J. Respir. Crit. Care Med.(Suppl), 2012 Abstract A6797.
45. Reisner, C., Fernandez, C., Darken, P., DePetrillo, P., St. Rose, E., Fischer, T., Strom, S., Kong, M., Wong, K., Siddiqui, S., Tardie, G., Orevillo, C., Pearl's PT010 triple combination provides comparable budesonide exposure to Symbicort and comparable glycopyrronium and formoterol exposure to PT003. Eur. Respir. J., 44(Suppl 58), 2014 Abstract 1891.
46. Rabe, K., Martinez, F., Rodriguez-Roisin, R., Fabbri, L.M., Ferguson, G.T., Jones, P., Rennard, S., Golden, M., Darken, P., Orevillo, C., Fischer, T., Reisner, C., PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. Eur. Respir. J., 46(Suppl 59), 2015 Abstract PA4363.
47. Mack, P., Doty, A., Schroeder, J., Vang, K., Dwivedi, S.W., Drug delivery from a novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI: evidence of consistency, robustness and patient-use reliability. Am. J. Respir. Crit. Care Med., 193, 2016 Abstract A5839.
48. Taylor, G., Warren, S., Orevillo, C., Maes, A., Martin, U., Dwivedi, S., Reisner, C., Pulmonary deposition of a novel LAMA/LABA Co-Suspension™ Technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020). Eur. Respir. J., 48(Suppl 60), 2016 Abstract OA4834.
49. Vos, W., De Backer, J., Schroeder, J., Sommerville, M., Dwivedi, S.K., De Backer, W., In-silico assessment of airway deposition using functional respiratory imaging for mono, dual and triple combination co-suspension metered dose inhaler formulations. Am. J. Respir. Crit. Care Med., 193, 2016 Abstract A5811.
50. Sovani, M.P., Whale, C.I., Oborne, J., Cooper, S., Mortimer, K., Ekström, T., Tattersfield, A.E., Harrison, T.W., Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. Br. J. Gen. Pract., 58(546), 2008 37–43. 7922.
51. Singh, D., Brooks, J., Hagan, G., Cahn, A., O'Connor, B.J., Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63:7 (2008), 592–598.
52. Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., Kessler, R., Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180:8 (2009), 741–750.
53. Siler, T.M., Kerwin, E., Singletary, K., Brooks, J., Church, A., Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD J. Chron. Obstruct. Pulm. Dis. 13:1 (2016), 1–10.
54. Singh, D., Papi, A., Corradi, M., Pavlisova, I., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., Vestbo, J., Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388:10048 (2016), 963–973.
55. D. Lomas, D. Lipson, H. Barnacle, R. Birk, N. Brealey, C.-Q. Zhu, M. Tabberer, Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: results of the FULFIL trial, presented at the European Respiratory Society International Congress, September 3–7 2016, Abstract PA4629.
56. Brusselle, G., Price, D., Gruffydd-Jones, K., Miravitlles, M., Keininger, D.L., Stewart, R., Baldwin, M., Jones, R.C., The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct Pulmon Dis. 10 (2015), 2207–2217.
57. Trelegy Ellipta. Research Triangle Park, NC: GlaxoSmithKline; 2017.
58. Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease. Retrieved from: http://clinicaltrials.gov (Identification No. NCT02536508). (Last Accessed 27 June 2017).
59. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos). Retrieved from: http://clinicaltrials.gov (Identification No. NCT02465567). (Last Accessed June 27 2017).
60. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With SymbicortR TurbuhalerR (Kronos). Retrieved from: http://clinicaltrials.gov (Identification No. NCT02497001). (Last Accessed 27 June 2017).
61. Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). Retrieved from http://clinicaltrials.gov/ (Identification No. NCT02196077). (Last Accessed 27 June 2017).
62. Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma. Retrieved from http://clinicaltrials.gov/ (Identification No. NCT02105012). (Last Accessed 27 June 2017).
63. Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma. Retrieved from http://clinicaltrials.gov/ (Identification No. NCT02433834). (Last Accessed 27 June 2017).
64. Price, D., Chrystyn, H., Kaplan, A., Haughney, J., Román-Rodríguez, M., Burden, A., Chisholm, A., Hillyer, E.V., von Ziegenweidt, J., Ali, M., van der Molen, T., Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol. Res. 4:4 (2012), 184–191.